Chemomab Therapeutics Ltd. CMMB
NASDAQ
| 06/30/2026 | 12/31/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | -- | -- | 3.65M | 3.51M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -- | -- | 12.67M | 14.18M | |
| Operating Income | -- | -- | -12.67M | -14.18M | |
| Income Before Tax | -- | -- | -11.83M | -13.40M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -- | -- | -11.83 | -13.40 | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -- | -- | -11.83M | -13.40M | |
| EBIT | -- | -- | -12.67M | -14.18M | |
| EBITDA | -- | -- | -12.61M | -14.12M | |
| EPS Basic | -- | -- | -188.88 | -241.71 | |
| Normalized Basic EPS | -- | -- | -- | -1.03 | |
| EPS Diluted | -- | -- | -188.88 | -241.71 | |
| Normalized Diluted EPS | -- | -- | -- | -1.03 | |
| Average Basic Shares Outstanding | -- | -- | 20.59M | 18.38M | |
| Average Diluted Shares Outstanding | -- | -- | 257.20K | 229.50K | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |